IPHA vs JYNT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IPHA exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a negative Price-to-Book ratio of -5.18, indicating negative shareholder equity. The company is experiencing a collapse in top-line growth with revenue declining 46.7% YoY, coupled with an unsustainable operating margin of -689.55%. While analysts maintain a 'strong_buy' rating with a $6.00 target, this is fundamentally disconnected from the current data-driven trajectory of value destruction and operational losses.
The Joint Corp. (JYNT) exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. Despite a low debt-to-equity ratio, the company suffers from negative ROE (-1.50%) and a staggering 5-year price decline of 83.5%. Valuation is prohibitively high with a Price/Book ratio of 8.20 and a Forward P/E of 38.80, which is not supported by a stagnant revenue growth rate of 3.10%. The massive reported earnings growth is likely a mathematical anomaly resulting from a low base effect rather than sustainable organic growth.
Compare Another Pair
Related Comparisons
IPHA vs JYNT: Head-to-Head Comparison
This page compares Innate Pharma S.A. (IPHA) and The Joint Corp. (JYNT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.